FDA approves first medication for obstructive sleep apnea — which also promotes weight loss

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).On Dec. 20, the FDA announced that the agency has approved Eli Lilly’s Zepbound (tirzepatide) to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.The drug is to be paired with a reduced-calorie diet and increased physical activity, the FDA noted.Sally Seymour, M.D., director of the Division of Pulmonology, Allergy and Critical Care in the FDA’s Center for Drug Evaluati ...